Juan Manuel Tovar Cabrera (@juanma3488) 's Twitter Profile
Juan Manuel Tovar Cabrera

@juanma3488

ID: 1534180974958985216

calendar_today07-06-2022 14:30:38

70 Tweet

22 Followers

86 Following

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

The most controversial meta-analysis of the year is now published on The Lancet. Anthracyclines improved outcomes when added to adjuvant taxanes, but only when administered concurrently. No apparent benefit for sequential schedules, which are current SoC. thelancet.com/journals/lance…

The most controversial meta-analysis of the year is now published on <a href="/TheLancet/">The Lancet</a>. Anthracyclines improved outcomes when added to adjuvant taxanes, but only when administered concurrently. No apparent benefit for sequential schedules, which are current SoC.
thelancet.com/journals/lance…
Alejandro Noguez (@alexnoguezr) 's Twitter Profile Photo

Check out our meta-analysis! 🇲🇽🇮🇹 Esophago-gastric adenocarcinoma is more common in older adults, but most clinical trials exclude them: “6,128 trials were reviewed, 92 included older patients … but only 7 reported efficacy or safety data” sciencedirect.com/science/articl…

Dr Sarah Sammons (@drsarahsam) 's Twitter Profile Photo

Keynote 522, beginning to see curves diverge in pCR groups possibly indicating longterm immunity benefits with pembrolizumab in pCR arm. Still does not answer question of adjuvant pembrolizumab being answered in OPTIMICE pCR. #bcsm

Keynote 522, beginning to see curves diverge in pCR groups possibly indicating longterm immunity benefits with pembrolizumab in pCR arm. Still does not answer question of adjuvant pembrolizumab being answered in OPTIMICE pCR.
#bcsm
Maite Bourlon (@bourlonmaite) 's Twitter Profile Photo

Happy to present the CheckMate9ER study ASCO #gu2024 👩🏻‍⚕️🇲🇽🦀 🔹 A P3 trial of cabo+nivolumab vs sunitinib in previously untreated advanced kidney cancer. 🔸@ 55m folow-up efficacy of the combo is maintained in OS, PFS and ORR 🔹Thanks for the great team and support! ALFREDO RONCORONI

Happy to present the CheckMate9ER study <a href="/ASCO/">ASCO</a> #gu2024 👩🏻‍⚕️🇲🇽🦀
🔹 A P3 trial of cabo+nivolumab vs sunitinib in previously untreated advanced kidney cancer. 
🔸@ 55m folow-up efficacy of the combo is maintained in OS, PFS and ORR
🔹Thanks for the great team and support! 

<a href="/URONCO/">ALFREDO RONCORONI</a>
José Ramón Llaca (@jrllaca) 's Twitter Profile Photo

George Kittle tal vez es el mejor personaje en toda la NFL Nadie como él para ponerle la mejor cara a la adversidad. En verdad lo amo…